Abstract
Brentuximab vedotin is a conjugate of anti CD30 antibody and monomethyl auristatin E - an antitubulin cytotoxic agent. Activity of brentuximab vedotin was confirmed in Hodgkin lymphoma and in anaplastic large T cell lymphoma.
Tumour cells in these lymphomas express the CD30 antigen. Brentuximab vedotin alone is indicated in relapsed Hodgkin lymphoma and anaplastic large T cell lymphoma due to its efficacy and acceptable toxicity profile.
The efficacy of brentuximab vedotin is currently evaluated in other CD30 positive lymphomas. The goal of ongoing studies is to evaluate the efficacy of bren-tuximab vedotin combined with standard chemotherapy.
The case report of a patient with second relapse of Hodgkin lymphoma treated with brentuximab vedotin is discussed in this article.